Gyros Protein Technologies introduces a multi-species kit for pharmacokinetic studies


New kit for early-stage biotherapeutic development, optimized for use in Gyrolab™ systems

Uppsala, Sweden, 05 April 2017: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, announced today it has introduced a new kit for early-stage biotherapeutic pharmacokinetic (PK) studies.

The new Gyrolab™ Generic PK Kit is optimized for use in automated, nanoliter-scale Gyrolab xP and Gyrolab xPlore™ systems, enabling quantification of human therapeutic antibodies. The kit is designed for use with several species of preclinical animal models, including mouse and cynomolgus monkey. While most other immunoassays for PK applications can take up to a full day to get results, the new Gyrolab Generic PK Kit saves the researcher a significant amount of time as pharmacokinetic results are generated in just one hour.

This generic kit for human therapeutic antibodies reduces the need for researchers to develop assays using costly analyte specific reagents. As the kit is supplied in an optimized, ready-to-use format, it also reduces the need for assay development, saving scientists’ time. The broad dynamic range of the kit minimizes the need for dilutions and repeats, which can introduce errors, supporting the needs of researchers to deliver high quality results. Moreover, Gyrolab assays consume nanoliter volumes, providing major preclinical benefits by enabling serial sampling of fewer mice to generate better data for more analyses while using less material.

Jasmine Gruia-Gray, VP Marketing, Gyros Protein Technologies, commented: “Part of Gyros Protein Technologies’ mission is to ensure that Gyrolab systems are recognized in the biotherapeutics industry as the gold standard for immunoassays in time-critical workflows. The new Gyrolab Generic PK Kit maximizes productivity while minimizing errors, and saving researchers’ time.”  

Established in March 2016 by the merger of Gyros AB and Protein Technologies, Inc., Gyros Protein Technologies combines Gyros’ microfluidics, systems development and immunoassay expertise with Protein Technologies’ deep knowledge in developing and manufacturing instruments for peptide synthesis. The Company provides customers an unrivaled range of peptide synthesis and bioanalytical tools for biotherapeutics discovery, development and bioprocessing

Gyrolab GPK Kit-web

For a high resolution image please contact Zyme Communications




For Gyros Protein Technologies AB

Katie Odgaard 
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947
Skype: kodgaard 

Notes to editors:

About Gyros Protein Technologies (For more information please click here)

Gyros Protein Technologies, enables peptide synthesis and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications.  Our low to mid-scale peptide synthesizer platforms are the Tribute®, Prelude® X, Symphony® X, and Sonata®. These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab™xP workstation and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide synthesis and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics.